Promise vs. Reality: The REGENXBIO Gene Therapy Performance Gap
NEW YORK
, March 5, 2026 /PRNewswire/ -- "Very promising results." That is how REGENXBIO, Inc. (NASDAQ: RGNX) characterized its RGX-111 gene therapy candidate as recently as January 2025. By January 28, 2026, the FDA had placed a clinical hold on the program after a CNS tumor was discovered in a trial participant, and RGNX shareholders lost $2.40 per share in a single trading session. Find out if you can recover your investment losses or contact Joseph E. Levi, Esq. at jlevi@SueWallSt.com or (888) SueWallSt.
Shares fell 17.8%, declining from $13.41 to $11.01, after the company disclosed the intraventricular CNS tumor and FDA clinical hold. The lead plaintiff deadline is April 14, 2026.
The Promise
Throughout the Class Period from February 9, 2022 to January 27, 2026, REGENXBIO projected confidence at every turn. The company described RGX-111 as its "second-most advanced clinical candidate" and a cornerstone of its "5x'25" strategy to have five gene therapies on the market or in late-stage development by 2025. In January 2025, management called RGX-111 and its partner therapy "potentially transformational medicines" when announcing a strategic partnership with Nippon Shinyaku Co., Ltd.
The Reality
On January 28, 2026, REGENXBIO revealed that a routine brain MRI identified an intraventricular CNS tumor in an asymptomatic five-year-old participant who had received RGX-111 four years earlier. Preliminary genetic analysis detected an AAV vector genome integration event linked to overexpression of a proto-oncogene (PLAG1). The FDA placed clinical holds on both RGX-111 and the related RGX-121 program.
The Numbers: Promised vs. Actual
-
Promised: "Well tolerated with no drug-related serious adverse events" (repeated across multiple earnings calls and press releases from 2022 through 2023)
-
Actual: A CNS tumor discovered in a pediatric trial participant, triggering an FDA clinical hold
-
Promised: RGX-111 positioned as a "potentially transformational medicine" with "very promising results" (January 2025 partnership announcement)
-
Actual: The FDA halted clinical development of both RGX-111 and RGX-121 just twelve months later
-
Promised: Part of a five-therapy commercialization strategy ("5x'25")
-
Actual: De-prioritized in November 2023 under circumstances the lawsuit contends reflected awareness of underlying safety problems
-
Promised: Fast Track FDA designation and a clear path to regulatory advancement
-
Actual: Full clinical hold with causality investigation ongoing
What the Lawsuit Alleges About the Gap
The complaint contends that the abrupt November 2023 decision to de-prioritize RGX-111 and seek "strategic alternatives" reflected internal awareness of safety problems that were not disclosed to investors. Despite this de-prioritization, management continued to describe the therapy's results as "very promising" when announcing the Nippon Shinyaku partnership over a year later.
"Companies that make specific promises to investors about future performance have an obligation to disclose known risks to those projections. When a gene therapy candidate is repeatedly described as transformational while serious safety signals allegedly go undisclosed, the gap between promise and reality can be measured in shareholder losses." -- Joseph E. Levi, Esq.
Speak with an attorney about recovering your RGNX losses or call Joseph E. Levi, Esq. at (212) 363-7500.
LEAD PLAINTIFF DEADLINE: April 14, 2026
Levi & Korsinsky, LLP is a nationally recognized shareholder rights firm. Over the past 20 years, the firm has secured hundreds of millions of dollars for aggrieved shareholders. Ranked in ISS Top 50 for seven consecutive years.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
jlevi@SueWallSt.com
Tel: (888) SueWallSt
Fax: (212) 363-7171
View original content:https://www.prnewswire.com/news-releases/rgnxs-transformational-promise-became-a-2-40-loss-for-investors-suewallst-302705701.html
SOURCE SueWallSt.com
